Hospira Reports First-Quarter 20...(pproximately 14000 employees. Learn more...),Health

               Private Securities Litigation Reform Act of 1995 --
                 A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks, uncertainties and assumptions, many of which are beyond Hospira's control, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

                                  Hospira, Inc.
                   Condensed Consolidated Statements of Income
                                   (Unaudited)
         (dollars and shares in millions, except for per share amounts)

                                                 Three Months Ended
                                                     March  31,
                                                   --
'/>"/>
SOURCE  Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Related medicine news :

1. Hospira to Host Conference Call for First-Quarter 2009 Results
2. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
3. Hospira Expands Board of Directors
4. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
5. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
6. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
7. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
8. Hospira Names Ken Meyers to Lead Human Resources
9. Hospira Reports Third-Quarter 2008 Results
10. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
11. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection